Exogenous progestins and breast cancer

Area of Science:

• Reproductive endocrinology and oncology
• Pharmacological effects of progestins
• Epidemiology of breast cancer

Background:

• Exogenous progestins are widely used for contraception and hormone replacement therapy.
• Biological mechanisms suggest progestins may interact with estrogen to promote breast cell proliferation.
• Existing research on progestin use and breast cancer risk presents mixed findings, necessitating further investigation.

Purpose of the Study:

• To review and synthesize current evidence on the association between exogenous progestin use and breast cancer risk.
• To identify gaps in knowledge regarding specific progestin types, dosages, and durations of use.
• To highlight the need for further research to clarify the complex relationship between progestins and breast cancer incidence.

Main Methods:

• Review of epidemiological studies and biological evidence on progestin exposure and breast cancer.
• Analysis of data from studies on combined oral contraceptives, progestin-only pills, and injectable contraceptives (DMPA).
• Examination of concerns regarding hormone replacement therapy and breast cancer risk.

Main Results:

• No specific progestin in combined oral contraceptives is linked to breast cancer.
• Progestin-only pills show no evidence of increased breast cancer risk; some studies suggest decreased risk with longer use.
• Injectable DMPA has shown mixed results, with some subgroups and recent use potentially linked to increased risk, but overall effects remain unclear.
• Evidence on hormone replacement therapy and breast cancer risk, particularly with extended use, is inconclusive and may be influenced by surveillance bias.

Conclusions:

• Current evidence does not establish a clear link between most exogenous progestin use (combined OCs, progestin-only pills) and increased breast cancer risk.
• Further research is crucial to understand the nuanced effects of specific progestins, particularly injectable contraceptives like DMPA and long-acting progestational agents, on breast cancer incidence.
• Future studies should investigate how duration, dosage, type, and timing of progestin use, along with concomitant estrogen use, influence breast cancer risk.